409 related articles for article (PubMed ID: 28426825)
1. Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation.
Gandhi RT; McMahon DK; Bosch RJ; Lalama CM; Cyktor JC; Macatangay BJ; Rinaldo CR; Riddler SA; Hogg E; Godfrey C; Collier AC; Eron JJ; Mellors JW;
PLoS Pathog; 2017 Apr; 13(4):e1006285. PubMed ID: 28426825
[TBL] [Abstract][Full Text] [Related]
2. Immunologic and Virologic Parameters Associated With Human Immunodeficiency Virus (HIV) DNA Reservoir Size in People With HIV Receiving Antiretroviral Therapy.
Blazkova J; Whitehead EJ; Schneck R; Shi V; Justement JS; Rai MA; Kennedy BD; Manning MR; Praiss L; Gittens K; Wender PA; Oguz C; Lack J; Moir S; Chun TW
J Infect Dis; 2024 Jun; 229(6):1770-1780. PubMed ID: 38128541
[TBL] [Abstract][Full Text] [Related]
3. Subclinical Cytomegalovirus DNA Is Associated with CD4 T Cell Activation and Impaired CD8 T Cell CD107a Expression in People Living with HIV despite Early Antiretroviral Therapy.
Christensen-Quick A; Massanella M; Frick A; Rawlings SA; Spina C; Vargas-Meneses M; Schrier R; Nakazawa M; Anderson C; Gianella S
J Virol; 2019 Jul; 93(13):. PubMed ID: 31019052
[TBL] [Abstract][Full Text] [Related]
4. Association of Male Sex and Obesity With Residual Plasma Human Immunodeficiency Virus 1 Viremia in Persons on Long-Term Antiretroviral Therapy.
Cyktor JC; Bosch RJ; Mar H; Macatangay BJ; Collier AC; Hogg E; Godfrey C; Eron JJ; McMahon DK; Mellors JW; Gandhi RT;
J Infect Dis; 2021 Feb; 223(3):462-470. PubMed ID: 32603416
[TBL] [Abstract][Full Text] [Related]
5. Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment.
Aamer HA; McClure J; Ko D; Maenza J; Collier AC; Coombs RW; Mullins JI; Frenkel LM
PLoS Pathog; 2020 Aug; 16(8):e1008791. PubMed ID: 32841299
[TBL] [Abstract][Full Text] [Related]
6. Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy.
Gandhi RT; Cyktor JC; Bosch RJ; Mar H; Laird GM; Martin A; Collier AC; Riddler SA; Macatangay BJ; Rinaldo CR; Eron JJ; Siliciano JD; McMahon DK; Mellors JW;
J Infect Dis; 2021 Feb; 223(2):225-233. PubMed ID: 32823274
[TBL] [Abstract][Full Text] [Related]
7. Lack of concordance between residual viremia and viral variants driving de novo infection of CD4(+) T cells on ART.
Puertas MC; Noguera-Julian M; Massanella M; Pou C; Buzon MJ; Clotet B; Stevenson M; Paredes R; Blanco J; Martinez-Picado J
Retrovirology; 2016 Aug; 13(1):51. PubMed ID: 27484989
[TBL] [Abstract][Full Text] [Related]
8. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size.
Jain V; Hartogensis W; Bacchetti P; Hunt PW; Hatano H; Sinclair E; Epling L; Lee TH; Busch MP; McCune JM; Pilcher CD; Hecht FM; Deeks SG
J Infect Dis; 2013 Oct; 208(8):1202-11. PubMed ID: 23852127
[TBL] [Abstract][Full Text] [Related]
9. Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels.
Hey-Cunningham WJ; Murray JM; Natarajan V; Amin J; Moore CL; Emery S; Cooper DA; Zaunders J; Kelleher AD; Koelsch KK;
AIDS; 2015 May; 29(8):911-9. PubMed ID: 25730509
[TBL] [Abstract][Full Text] [Related]
10. Activated PD-1+ CD4+ T cells represent a short-lived part of the viral reservoir and predict poor immunologic recovery upon initiation of ART.
Eller MA; Hong T; Creegan M; Nau ME; Sanders-Buell E; Slike BM; Krebs SJ; Ratto-Kim S; McElrath MJ; Katabira ET; Bolton DL; Michael NL; Robb ML; Tovanabutra S; Baeten JM; Sandberg JK
AIDS; 2020 Feb; 34(2):197-202. PubMed ID: 31764072
[TBL] [Abstract][Full Text] [Related]
11. Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.
Price DA; Scullard G; Oxenius A; Braganza R; Beddows SA; Kazmi S; Clarke JR; Johnson GE; Weber JN; Phillips RE
J Virol; 2003 May; 77(10):6041-9. PubMed ID: 12719595
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy.
Besson GJ; Lalama CM; Bosch RJ; Gandhi RT; Bedison MA; Aga E; Riddler SA; McMahon DK; Hong F; Mellors JW
Clin Infect Dis; 2014 Nov; 59(9):1312-21. PubMed ID: 25073894
[TBL] [Abstract][Full Text] [Related]
13. Brief Report: No Evidence for an Association Between Statin Use and Lower Biomarkers of HIV Persistence or Immune Activation/Inflammation During Effective ART.
Bedimo RJ; Mar H; Bosch RJ; Drechsler H; Cyktor JC; Macatangay BJC; Lalama C; Rinaldo C; Collier A; Godfrey C; Hogg E; Hensel C; Eron JJ; Mcmahon DK; Mellors JW; Tebas P; Gandhi RT;
J Acquir Immune Defic Syndr; 2019 Oct; 82(2):e27-e31. PubMed ID: 31335587
[TBL] [Abstract][Full Text] [Related]
14. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA.
Goicoechea M; Smith DM; Liu L; May S; Tenorio AR; Ignacio CC; Landay A; Haubrich R
J Infect Dis; 2006 Jul; 194(1):29-37. PubMed ID: 16741879
[TBL] [Abstract][Full Text] [Related]
15. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
Cillo AR; Hilldorfer BB; Lalama CM; McKinnon JE; Coombs RW; Tenorio AR; Fox L; Gandhi RT; Ribaudo H; Currier JS; Gulick RM; Wilkin TJ; Mellors JW
AIDS; 2015 Oct; 29(16):2121-9. PubMed ID: 26544577
[TBL] [Abstract][Full Text] [Related]
16. Antigen Presenting Cells Contribute to Persistent Immune Activation Despite Antiretroviral Therapy Initiation During Hyperacute HIV-1 Infection.
Naidoo KK; Ndumnego OC; Ismail N; Dong KL; Ndung'u T
Front Immunol; 2021; 12():738743. PubMed ID: 34630420
[TBL] [Abstract][Full Text] [Related]
17. Rapid CD4 decline prior to antiretroviral therapy predicts subsequent failure to reconstitute despite HIV viral suppression.
Darraj M; Shafer LA; Chan S; Kasper K; Keynan Y
J Infect Public Health; 2018; 11(2):265-269. PubMed ID: 28826735
[TBL] [Abstract][Full Text] [Related]
18. Cell-Associated HIV-1 Unspliced-to-Multiply-Spliced RNA Ratio at 12 Weeks of ART Predicts Immune Reconstitution on Therapy.
Scherpenisse M; Kootstra NA; Bakker M; Berkhout B; Pasternak AO
mBio; 2021 Mar; 12(2):. PubMed ID: 33688002
[TBL] [Abstract][Full Text] [Related]
19. Intracellular HIV-1 RNA and CD4+ T-cell activation in patients starting antiretrovirals.
El-Diwany R; Breitwieser FP; Soliman M; Skaist AM; Srikrishna G; Blankson JN; Ray SC; Wheelan SJ; Thomas DL; Balagopal A
AIDS; 2017 Jun; 31(10):1405-1414. PubMed ID: 28358734
[TBL] [Abstract][Full Text] [Related]
20. Low CD4 T-cell counts despite low levels of circulating HIV: insights from the comparison of HIV-1 infected patients with a discordant response to antiretroviral therapy to patients with untreated advanced HIV-2 disease.
Albuquerque AS; Foxall RB; Cortesão CS; Soares RS; Doroana M; Ribeiro A; Lucas M; Antunes F; Victorino RM; Sousa AE
Clin Immunol; 2007 Oct; 125(1):67-75. PubMed ID: 17692571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
